Tradeoff: The solution is stronger, so smaller doses may require fewer syringe units
Brandon Pearson, PhD As of mid-September, the MDL contained 265 cases
He mentioned, "There hasn't been a notable opposition from our members in challenging these items, possibly because they don't meet the criteria under 503A." According to Section 503A of the Food, Drug & Cosmetic Act, an eligible bulk drug substance for compounding must be a component of an FDA-approved drug, must have a USP or NF monograph, or must appear on the FDAs 503A Bulks List or Interim Bulks List Category 1
Also see: Is there a risk of liver toxicity with certain supplements
------------ Read blog, An Overview of Active Mass Tort Litigation in 2026 ------------ Evaluating Damages in GLP-1 Lawsuits 1
Tesamorelin is particularly effective for visceral belly fat, while CJC-1295/ipamorelin supports body recomposition through growth hormone optimization